

JC10 Rec'd PCT/PTO 27 MAY 2005

PCT



Practitioner's Docket No. 2002DE108

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Joachim Weber et al.

Application No.: 10/511,857

Group No.:

Filed: October 15, 2004

For: Method for Producing Vatable Organic Pigments

Commissioner for Patent

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

**CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10\***  
(When using Express Mail, the Express Mail label number is **mandatory**;  
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10\*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_ (mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office (703) \_\_\_\_-\_\_\_\_.

Date:

May 25 2005

Signature

Jackie L. Wise

Jackie L. Wise  
(type or print name of person certifying)

**\*WARNING:**

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).

"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.


Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. ☒ Enclosures accompanying this Information Disclosure Statement are:
  - 1a. ☒ Form PTO-1449.
  - 1b. ☒ Copies of Information Disclosure Statement citations.
  - 1c. ☐ PCT Search Report
  - 1d. ☐ Copies of Co-pending U.S. Applications.
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☒ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☐ This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

7. ☒ The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
8. ☐ In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:


Respectfully submitted,



Anthony A. Bisulca  
Registration No. 40,913

**CUSTOMER NO. 25,255**

Clariant Corporation  
Industrial Property Department  
4000 Monroe Road  
Charlotte, North Carolina 28205  
Telephone: 704/331-7151  
Facsimile: 704/331-7707

<p>FORM PTO-1449</p> <p>U.S. DEPARTMENT OF COMMERCE</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(37 CFR 1.98(b))</p> 	<p>ATTY. DOCKET NO.</p> <p>2002DE108</p>	<p>SERIAL NO.</p> <p>10/511,857</p>
	<p>APPLICANT: Joachim Weber et al.</p>	
	<p>FILING DATE:</p> <p>10/15/2004</p>	<p>GROUP:</p>

## U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Dte	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6521756	2/18/03	Weber et al.			
	AB	4189582	2/19/80	Hoch et al.			
	AC	4217455	8/12/80	Hoch et al.			
	AD	6646126	11/11/03	Webber et al.			
	AE	4742170	5/3/88	Spietschka et al.			
	AF	4705572	11/10/87	Spietschka et al.			
	AG	5626662	5/6/97	Urban et al.			
	AH	5614015	3/25/97	Urban et al.			
	AI	6174361	1/16/01	Urban et al.			
	AJ	6521756	2/18/03	Weber et al.			
	AK	5062577	11/5/91	Schmitt et al.			
	AL	2905685	10/22/59	Eckert et al.			
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						

**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## FOREIGN PATENT OR PUBLISHED FOREIGN APPLICATION

		DOCUMENT NUMBER	PUB. DATE	COUNTRY		TRANSLATION
	BA	DE 2727484	1/11/79	Germany		See AB above
	BB	DE 2803362	10/26/78	Germany		See AC above
	BC	DE 2854190	3/27/80	Germany		English Abstract
	BD	EP 1130062	9/5/01	EPO		See AA & AD above
	BE	EP 0176899	4/9/86	EPO		See AE above
	BF	EP 0213281	3/11/87	EPO		See AF above
	BG	EP 0678559	10/25/95	EPO		See AG above
	BH	EP 0702060	3/20/96	EPO		See AH above
	BI	EP 0979846	2/16/00	EPO		See AI above
	BJ	DE 10005186	8/9/01	Germany		See AJ & AD above
	BK	DE 3716587	2/11/93	Germany		See AK above
	BL	DE 1113773	3/22/62	Germany		English Abstract
	BM	DE 1067157	4/7/60	Germany		See AL above
	BN					
	BO					
	BP					
	BQ					
	BR					
	BS					
	BT					
	BU					
	BV					
	BW					
	BX					

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication\*\*)

CA		Copy of Search Report for PCT/EP 03/02730, mailed 7/16/2003
CB		English Translation of IPER for PCT/EP 03/02730, 1/27/2005
CC		
CD		
CE		
CF		
CG		
CH		
CI		
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		